Valeant Pharmaceuticals (TSX: VRX) has announced that it will make an enhanced rebate program available to reduce the price of Nitropress (nitroprusside) and Isuprel (isoproterenol) to all hospitals in the USA.
The Canada-based company, which has come under investigation by the US Senate over dramatic price increases it imposed, including those for the cardiac-care drugs Nitropress and Isuprel.
Company bosses have admitted that mistakes were made over such price hikes and it has set up its own Patient Access and Pricing Committee as part of promises to clean up its act.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze